Stock Analysis, Dividends, Split History

TAP / Molson Coors Brewing Co. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price64.04
Volume1,592,100.00
Market Cap ($M)12,351.27
Enterprise Value ($M)24,028.67
Book Value ($M)13,576.60
Book Value / Share69.40
Price / Book0.91
NCAV ($M)-13,876.80
NCAV / Share-70.94
Price / NCAV-0.89
Share Statistics
Common Shares Outstanding3 2,560,568
Common Shares Outstanding2 2,878,535
Common Shares Outstanding 14,691,571
Common Shares Outstanding4 195,427,749
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.05
Return on Equity (ROE)0.13
Balance Sheet (mrq) ($M)
Assets30,560.90
Liabilities16,764.30
Quick Ratio0.51
Current Ratio0.66
Income Statement (mra) ($M)
Revenues0.00
Sales Revenue Goods Net11,002,800,000.00
Sales Revenue Goods Gross13,471,500,000.00
Operating Income1,725.10
Net Income1,436.40
Earnings Per Share Diluted6.53
Earnings Per Share Basic6.57
Cash Flow Statement (mra) ($M)
Cash From Operations1,866.30
Cash from Investing-538.20
Cash from Financing-538.20
Identifiers and Descriptors
CUSIP60871R209
Central Index Key (CIK)24545
Industry Groups
SIC 2082 - Malt Beverages

Split History

Stock splits are used by Molson Coors Brewing Co. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Trapeze Asset Management Q2 2018 Letter: The Quality Quandary

2018-09-11 seekingalpha
As value investors, we are always on the lookout for bargains - stocks or bonds that are trading at prices below our estimate of Fair Market Value (FMV). Both research and common sense dictate that the greater the discrepancy between price and FMV, the better it provides a higher possible margin of safety and implied upside. However, securities are often detached from their FMVs because the business is suffering, leaving investors to figure out whether the issues at hand will be minor and temporary or debilitating and permanent. (26-0)

Cronos Group Stock Is Your Classic High-Risk, High-Reward Play

2018-09-07 investorplace
Cronos Group (NASDAQ:CRON) had a remarkable week in the markets, which should surprise no one. As a marijuana-related investment, CRON stock is liable to make insane moves. Fortunately for long-side speculators, shares moved in the right direction. But just how sustainable is this swing? (9-6)

Now Is Almost Certainly the Best Time to Dump Cronos Stock

2018-09-05 investorplace
Cronos Group (NASDAQ:CRON) has been on a tear, with Cronos stock nearly doubling before settling down to its current price. But then again, it was a great month for investors in marijuana. (9-4)

21 Beverage Stocks to Buy for the Contrarian-Minded

2018-08-27 investorplace
Researching beverage stocks to buy is a smart move because of the simple fact that the sector is largely secular. No matter how the underlying economy is performing, people still need to drink. That constant demand is a significant advantage for companies in the field. (43-2)

The Cisco Of Pot

2018-08-27 seekingalpha
It will very quickly make Canopy the dominant product developer, patent owner, and consolidator of the industry. (21-5)

CUSIP: 60871R209